




RealRate

# HEALTH SERVICES 2025

## Lisata Therapeutics INC Rank 22 of 67





RealRate

# HEALTH SERVICES 2025

## Lisata Therapeutics INC Rank 22 of 67



The relative strengths and weaknesses of Lisata Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lisata Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 128% points. The greatest weakness of Lisata Therapeutics INC is the variable Net Income, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 178%, being 25% points above the market average of 154%.

| Input Variable                        | Value in 1000 USD |
|---------------------------------------|-------------------|
| Assets, Current                       | 34,578            |
| Assets, Non-Current                   | 160               |
| Cost of Goods and Services Sold       | 0                 |
| Depreciation, Depletion, Amortization | 0                 |
| General and Administrative Expense    | 12,075            |
| Goodwill Impairment Loss              | 0                 |
| Intangible Assets                     | 0                 |
| Labor Expense                         | 0                 |
| Liabilities, Current                  | 5,613             |
| Long Term Liabilities                 | 72                |
| Operating Costs and Expenses          | 0                 |
| Other Assets                          | 192               |
| Other Compr. Net Income               | -39               |
| Other Expenses                        | 10,536            |
| Other Liabilities                     | 0                 |
| Other Net Income                      | 1,626             |
| Other Revenues                        | 1,000             |
| Property Plant and Equipment          | 72                |
| Research And Development Expense      | 0                 |
| Selling and Marketing Expense         | 0                 |

| Output Variable             | Value in 1000 USD |
|-----------------------------|-------------------|
| Assets                      | 35,002            |
| Liabilities                 | 5,685             |
| Expenses                    | 22,611            |
| Revenues                    | 1,000             |
| Stockholders Equity         | 29,317            |
| Net Income                  | -19,985           |
| Comprehensive Net Income    | -20,024           |
| BaseVar                     | 32,982            |
| ECR before LimitedLiability | 111%              |
| Economic Capital Ratio      | 178%              |